Overview Scientific Committee Program Speakers Abstract Submission Sponsors Visit Qatar

 

Recent Advances in Primary Immunodysregulation Disorders (RAPID)

Target Audience

  • Clinicians and scientists who treat or study patients with primary/genetic immune dysregulation disorders.
Day 1: Thursday
7:30 8:30 Registration
8:30 9:00 Opening Session and Welcome Remarks
9:00 10:30

Session 1: Primary Immunodeficiency spectrum: What is new

Chairs:

  • Nicholas van Panhuys, Sidra Medicine
  • Elif Aydiner, Marmara University, Turkey
  • Overview on What’s new in IEI – spectrum & diagnosis
    • Kate Sullivan, Childrens' Hospital of Philadelphia
  • Inflammatory bowel disease - gene, mechanisms and treatments
    • Holm Uhlig, Oxford University
  • Endosome dysfunction leads to gain-of-function TLR7 and human lupus
    • Fabian Hauck, LMU Munich University Hospital
  • An immunodysregulatory syndrome caused by aberrant G-protein signaling
    • Helen Su, NIAID/NIH
10:30 11:00 Coffee break
11:00 12:15 Abstract Presentations on the PID spectrum Best abstracts will be selected for oral presentation

Chairs:

  • Waleed Al-Herz, Kuwait University
  • Aisha Elmarsafy, Cairo University
12:15 1:30 Lunch

Career Development Panel Session

Chairs:

  • Deena Wafadari, Mohamed Bin Rashid University, UAE
  • Rafah Mackeh, Sidra Medicine

Panelists:  

  • Medhat Askar, Associate Vice President for Clinical Affairs and Professor of Immunology at Qatar University
  • Suleiman Al-Hammadi, Dean of College of Medicine, Mohammed Bin Rashid University, UAE
  • Nayef Mazloum, Assistant Dean for Student Research at WCM-Q and Assistant Professor of Microbiology and Immunology at WCM-Q and HBKU
  • Samar Al Emadi, Chief of Rheumatology Division and Program Director of Rheumatology Fellowship Program, HMC
  • Maryam Al-Nesf, Head of Allergy & Immunology Section and Allergy & Immunology Program Director, HMC
  • Ibrahim Janahi, Chair of Medical Education and Division Chief of Pulmonology at Sidra Medicine
1:30 3:30

Diagnostic challenges in Inborn errors of immunity (Primary Immunodeficiency)

Chairs:

  • Suleiman Al-Hammadi, Mohammed Bin Rashid University, UAE
  • Michel Massaad, American University of Beirut
  • The Ever Changing Genetic Landscape of IEI
    • Jolan Walter, University of South Florida
  • Genetics of IEI in the MENA region
    • Hamoud Almousa, King Faisal Specialist Hospital & Research Center
  • Importance of functional investigations of Variants of Uncertain Significance (VUS)
    • Amel Hassan, Qatar University
  • The subtleties of JAK-STAT biology within the immune system in health and disease
    • Raphaela Goldbach-Mansky, NIAID/NIH
  • Rheumatological complications of primary immune dysregulation
    • Raphaela Goldbach-Mansky, NIAID/NIH
3:30 4:00 Coffee break
4:00 5:15

Genetic Screening for IEI in the MENA region - Panel discussions

Moderators:

  • Bandar Al-Saud, King Faisal Specialist Hospital and Research Centre, KSA
  • Bernice Lo, Sidra Medicine

Introductory 15 min talk by Donald Love

Panelists to address the following discussion questions:

  • Subcontracting or Developing institutional capacities?
  • What strategy for screening: WES or gene panels?
  • Bioinformatics capacities to be developed locally or not?
  • Integrating AI with bioinformatics

Panelists:

  • Anas Alazami, King Faisal Specialist Hospital and Research Centre
  • Imen Ben Mustapha, Pasteur Institute of Tunis
  • Serdar Ceylaner, Lokman Hekim Üniversitesi
  • Wangling Yang, The University of Hong Kong
  • Donald Love, Sidra Medicine
Day 2: Friday
8:00 10:00

Clinical Presentations of Organ-based Immune Dysregulation

Chairs:

  • Gehad Elghazali, United Arab Emirates University
  •  Sharon Bout-Tabaku, Sidra Medicine
  • Clinical features of monogenic immunodysregulation diseases from the Middle East and North Africa registry
    • Hassan Abolhassani, Tehran University of Medical Sciences & Karolinska Institutet
  • Allergic and cutaneous presentations in patients with primary immunodysregulation disorders.
    • Ridha Barbouche, Arabian Gulf University
  • Malıgnancy as a presenting feature or complication of primary immunodysregulation
    • Nima Rezaei, Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences
  • Inflammatory bowel disease: clinical pearls for monogenic vs. polygenic presentation and prognosis
    • Mamoun Elawad, Sidra Medicine
  • The frontiers between hypogammaglobulinemia and immune dysregulation among the spectrum of CVID patients
    • Ghassan Dbaibo, American University of Beirut
10:00 10:30 Coffee break
10:30 11:30

Abstract Presentations on Organ-based manifestations of immune dysregulation

Chairs:

  • Ibtihal Benhsaien, King Hassan II University, Morocco
  • Buthaina Al-Adba, Sidra Medicine
Best abstracts will be selected for oral presentation
11:30 12:30

Lunch / Jumma prayer

Sponsor workshops:  Biotest (starting 12:00 pm)

  • Mohammed Yousuf Karim, Sidra Medicine

Case presentation: Clinical pearls to distinguish IEI from secondary immunodeficiency

12:30 2:00

Immune Dysregulation Disorders: Emerging Therapeutic Strategies and Modalities

Chairs:

  • Mohammed Yousuf Karim, Sidra Medicine
  • Deniz Çağdaş Ayvaz, Hacettepe University, Turkey

 

  • Vicki Modell Memorial Lecture
    Updates from the Primary Immune Deficiency Treatment Consortium (PIDTC)
    • Jennifer Puck, University of California – San Francisco
  • Leniolisib for APDS/PASLI Disease
    • Mike Lenardo, NIAID/NIH
  • Complement Inhibitor Therapy for CHAPLE Disease
    • Ahmet Ozen, Marmara University
2:00 3:00 Poster Session
3:00 4:00

Recent Advances in Corrective Therapies for Inborn Errors of Immunity (IEI)

Chairs:

  • Aydan Ikincioğulları, Ankara University Medical School, Turkey
  •  Raed Alzyoud, Queen Rania Children's Hospital, Jordan
  • Gene Therapy for Inborn Errors of Immunity: Current Progress and Prospects
    • Maria Pia Cicalese, San Raffaele Telethon Institute for Gene Therapy
  • Lentivirus gene therapy trial for Artemis (DCLRE1C) deficient SCID
    • Jennifer Puck, University of California – San Francisco
  • Expanding the Scope of HSCT in the Treatment of IEIs Beyond SCID.
    • Danielle Arnold, Center for Cancer Research/NCI/NIH
4:00 5:30

Viewpoint topics

Moderators:

  • Brahim Belaid, University of Algiers 1, Algeria
  • Ihsan Gursel, Bilkent University, Turkey

Curative therapies vs. pharmacotherapy in inborn errors of immunity

Topic 1: LRBA Deficiency/CTLA4 Haploinsufficiency Disorders

  • The latest advancements, benefits, and limitations of pharmacotherapy.
    • Safa Baris, Marmara University, School of Medicine
  • The effectiveness, challenges, and potential of Hematopoietic Stem Cell Transplantation (HSCT).
    • Figen Doğu, Ankara University, Faculty of Medicine

Topic 2: Chronic Granulomatous Disease

  • Insights into pharmacological interventions, their impact, and scope.
    • Jennifer W. Leiding, University of South Florida
  • HSCT and emerging gene therapy options: when to consider curative therapies in CGD.
    • Danielle Arnold, National Cancer Institute/NIH
5:30 6:00 Wrap-up and closing